Pulicatins F

Pulicatins F

SCHEMBL12469099

NC(=O)c1csc(-c2ccccc2O)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 3/20 1.00
ACHE P22303 3/20 0.64
CYP2C9 P11712 1/20 0.50
SCN9A Q15858 1/20 0.50
CYP2C19 P33261 1/20 0.49
RAB9A P51151 2/20 0.47
CASP3 P42574 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
THRB P10828 1/20 0.46
CYP19A1 P11511 1/20 0.45
MAOA P21397 1/20 0.44
HDAC1 Q13547 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
PIM1 P11309 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9823334 0.85 HTR2B (0.73) HTR2BACHERAB9ACASP3SMN1; SMN2
SCHEMBL15423067 0.83 HTR2B (0.71) HTR2BACHERAB9ACASP3SMN1; SMN2
SCHEMBL2553228 0.83 HTR2B (0.70) HTR2BACHECYP2C9CYP2C19RAB9A
SCHEMBL14463683 0.80 HTR2B (0.66) HTR2BACHECYP2C9SCN9ACYP2C19
SCHEMBL168519 0.79 HTR2B (0.66) HTR2BACHECYP2C9SCN9ACYP2C19
SCHEMBL13548732 0.76 HTR2C (0.62) HTR2BACHECYP2C9SCN9ACYP2C19
SCHEMBL28866158 0.76 HTR2B (0.61) HTR2BACHECYP2C9SCN9ACYP2C19
SCHEMBL2551417 0.76 HTR2B (0.61) HTR2BACHECYP2C19RAB9ASMN1; SMN2
SCHEMBL9830640 0.75 HTR2B (0.60) HTR2BCYP2C9CYP2C19RAB9ACASP3
SCHEMBL31351218 0.75 HTR2B (0.60) HTR2BACHECYP2C9SCN9ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106573927-B Oxyclohepten-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use 豪夫迈·罗氏有限公司 2019-09-27 CN claimed
US-9751847-B2 Methods and compositions related to neuroactive thiazoline compounds UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2017-09-05 US disclosed
US-9751847-B2 Methods and compositions related to neuroactive thiazoline compounds UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2017-09-05 US disclosed
US-9751847-B2 Methods and compositions related to neuroactive thiazoline compounds UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2017-09-05 US disclosed
US-20140018400-A1 METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-01-16 US disclosed
US-20140018400-A1 METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-01-16 US disclosed
US-20140018400-A1 METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-01-16 US disclosed
WO-2012051502-A1 METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2012-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018400-A1 METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS TACR2, TACR3, TACR1 HTR2B 58/4885ACHE 167/4885CYP2C9 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.